NZ733366A - Purification of iduronate-2-sulfatase - Google Patents

Purification of iduronate-2-sulfatase

Info

Publication number
NZ733366A
NZ733366A NZ733366A NZ73336613A NZ733366A NZ 733366 A NZ733366 A NZ 733366A NZ 733366 A NZ733366 A NZ 733366A NZ 73336613 A NZ73336613 A NZ 73336613A NZ 733366 A NZ733366 A NZ 733366A
Authority
NZ
New Zealand
Prior art keywords
sulfatase
iduronate
purification
seq
purified recombinant
Prior art date
Application number
NZ733366A
Other languages
English (en)
Inventor
Dave Nichols
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49778401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ733366(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Priority to NZ743910A priority Critical patent/NZ743910A/en
Publication of NZ733366A publication Critical patent/NZ733366A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NZ733366A 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase NZ733366A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ743910A NZ743910A (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666733P 2012-06-29 2012-06-29
NZ703093A NZ703093A (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase

Publications (1)

Publication Number Publication Date
NZ733366A true NZ733366A (en) 2019-12-20

Family

ID=49778401

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ733366A NZ733366A (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase
NZ743910A NZ743910A (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase
NZ703093A NZ703093A (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ743910A NZ743910A (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase
NZ703093A NZ703093A (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase

Country Status (39)

Country Link
US (7) US9051556B2 (cg-RX-API-DMAC7.html)
EP (2) EP3441398A1 (cg-RX-API-DMAC7.html)
JP (4) JP6171007B2 (cg-RX-API-DMAC7.html)
KR (5) KR101380740B1 (cg-RX-API-DMAC7.html)
CN (3) CN107596358A (cg-RX-API-DMAC7.html)
AR (1) AR091647A1 (cg-RX-API-DMAC7.html)
AU (3) AU2013282395C1 (cg-RX-API-DMAC7.html)
BR (1) BR112014032567B1 (cg-RX-API-DMAC7.html)
CA (2) CA2877517C (cg-RX-API-DMAC7.html)
CL (1) CL2014003567A1 (cg-RX-API-DMAC7.html)
CO (1) CO7240396A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140588A (cg-RX-API-DMAC7.html)
CY (1) CY1121519T1 (cg-RX-API-DMAC7.html)
DK (1) DK2867245T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2014000294A (cg-RX-API-DMAC7.html)
EA (2) EA202090044A1 (cg-RX-API-DMAC7.html)
ES (1) ES2689468T3 (cg-RX-API-DMAC7.html)
GT (1) GT201400303A (cg-RX-API-DMAC7.html)
HK (3) HK1209431A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20181897T1 (cg-RX-API-DMAC7.html)
HU (1) HUE040769T2 (cg-RX-API-DMAC7.html)
IL (4) IL236315A (cg-RX-API-DMAC7.html)
LT (1) LT2867245T (cg-RX-API-DMAC7.html)
MX (3) MX366906B (cg-RX-API-DMAC7.html)
MY (3) MY180287A (cg-RX-API-DMAC7.html)
NZ (3) NZ733366A (cg-RX-API-DMAC7.html)
PE (1) PE20150720A1 (cg-RX-API-DMAC7.html)
PH (3) PH12014502871A1 (cg-RX-API-DMAC7.html)
PL (1) PL2867245T3 (cg-RX-API-DMAC7.html)
PT (1) PT2867245T (cg-RX-API-DMAC7.html)
RS (1) RS58005B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201408761VA (cg-RX-API-DMAC7.html)
SI (1) SI2867245T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800612T1 (cg-RX-API-DMAC7.html)
TR (1) TR201815811T4 (cg-RX-API-DMAC7.html)
TW (2) TWI553120B (cg-RX-API-DMAC7.html)
UA (2) UA129561C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014005014A2 (cg-RX-API-DMAC7.html)
ZA (2) ZA201409397B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009018122A2 (en) 2007-07-27 2009-02-05 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the cns
EP2485761B1 (en) 2009-10-09 2019-02-27 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
CN109641971B (zh) 2016-08-25 2023-04-04 Jcr制药股份有限公司 抗体融合蛋白的制造方法
CN106282231B (zh) * 2016-09-06 2020-01-03 陕西慧康生物科技有限责任公司 粘多糖贮积症ii型动物模型的构建方法及应用
CN106428420B (zh) * 2016-10-17 2018-08-21 上海江南长兴造船有限责任公司 一种用于超大型集装箱船止裂钢舱口围的安装的方法
US20200277584A1 (en) 2017-10-02 2020-09-03 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
EP3898689A1 (en) * 2018-12-20 2021-10-27 Armagen, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein
US20220098279A1 (en) * 2019-01-30 2022-03-31 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
AU2020398898A1 (en) 2019-12-09 2022-07-21 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
JP2023546682A (ja) * 2020-10-23 2023-11-07 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼの製造中に総シアル酸含量（ｔｓａｃ）を制御する方法
CN117042791A (zh) 2021-02-12 2023-11-10 阿雷克森制药公司 碱性磷酸酶多肽及其使用方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
CA2185324A1 (en) 1994-03-16 1995-09-21 Steven D. Rosen Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
EP2221361A3 (en) 1996-08-30 2011-02-09 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
WO2001018022A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences, Inc. 52 human secreted proteins
WO2000050443A2 (en) 1999-02-26 2000-08-31 Millennium Pharmaceutcals, Inc. Secreted proteins and uses thereof
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
ATE348173T1 (de) 1999-04-26 2007-01-15 Genentech Inc Zellenzuchtverfahren für glycoproteine
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
WO2001060991A2 (en) 2000-02-17 2001-08-23 Incyte Genomics, Inc. Human kinases
CA2400638A1 (en) 2000-03-17 2001-09-27 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
WO2002098455A2 (en) 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human arylsulfatase a
WO2003102132A2 (en) 2002-04-26 2003-12-11 Genetech, Inc. Non-affinity purification of proteins
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
PL377731A1 (pl) 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Sposoby hodowli komórek ssaczych do wytwarzania białka
JP4606712B2 (ja) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
EP2325301B1 (en) 2003-02-11 2015-09-02 Shire Human Genetic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and others using a formylglycine generating enzyme (FGE)
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
WO2005073367A1 (en) 2004-01-30 2005-08-11 Zymenex A/S Production and purification of recombinant arylsulfatase a
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
SI2267024T1 (sl) 2005-06-03 2012-09-28 Ares Trading Sa Proizvodnja rekombinantnega IL-18 vezavnega proteina
CN101437839A (zh) 2006-03-20 2009-05-20 米德列斯公司 蛋白质纯化
JP4458377B2 (ja) 2007-06-29 2010-04-28 キヤノン株式会社 プロセスカートリッジ及び電子写真画像形成装置
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
US8128925B2 (en) * 2008-01-18 2012-03-06 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
EP2485761B1 (en) 2009-10-09 2019-02-27 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
WO2011108451A1 (ja) * 2010-03-01 2011-09-09 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
JP6063380B2 (ja) * 2010-06-25 2017-01-18 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド サンフィリポ症候群ｂ型の処置
SMT201900594T1 (it) 2010-06-25 2019-11-13 Shire Human Genetic Therapies Metodi e composizioni per il rilascio nell’snc di iduronato-2-solfatasi
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
CN103153337A (zh) * 2010-09-28 2013-06-12 共立制药股份有限公司 黏膜佐剂组合物
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR20130114704A (ko) 2011-01-31 2013-10-17 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. 동적으로 튜닝 가능한 산란각을 갖는 산광기
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) * 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
KR20190062745A (ko) 2017-11-29 2019-06-07 주식회사 위니플 쇼핑몰 모바일앱 빌더

Also Published As

Publication number Publication date
US20190359958A1 (en) 2019-11-28
US20210317426A1 (en) 2021-10-14
CO7240396A2 (es) 2015-04-17
PH12020500027A1 (en) 2021-03-15
IL261264A (en) 2018-10-31
AU2016200469B2 (en) 2017-10-12
PH12014502871B1 (en) 2015-02-23
UA129561C2 (uk) 2025-06-04
TWI553120B (zh) 2016-10-11
IL236315A0 (en) 2015-02-26
JP2015523072A (ja) 2015-08-13
KR20220002227A (ko) 2022-01-06
MX393364B (es) 2025-03-19
IL261264B (en) 2021-10-31
ZA201409397B (en) 2019-10-30
CN107596358A (zh) 2018-01-19
TW201703794A (zh) 2017-02-01
AU2013282395B2 (en) 2015-12-03
LT2867245T (lt) 2018-11-12
US12359178B2 (en) 2025-07-15
MX2019008914A (es) 2019-09-26
KR101380740B1 (ko) 2014-04-11
CA2877517A1 (en) 2014-01-03
AU2018200230A1 (en) 2018-02-01
HK1249026A1 (zh) 2018-10-26
SMT201800612T1 (it) 2019-01-11
US11530393B2 (en) 2022-12-20
JP6171007B2 (ja) 2017-07-26
MX2015000190A (es) 2015-04-08
JP7594365B2 (ja) 2024-12-04
HK1249027A1 (zh) 2018-10-26
CY1121519T1 (el) 2020-05-29
NZ743910A (en) 2019-12-20
US20240043817A1 (en) 2024-02-08
SG11201408761VA (en) 2015-01-29
RS58005B1 (sr) 2019-02-28
US9051556B2 (en) 2015-06-09
CA2877517C (en) 2018-07-31
BR112014032567A2 (pt) 2017-08-01
IL236315A (en) 2016-11-30
MY157087A (en) 2016-04-19
ES2689468T3 (es) 2018-11-14
KR20190064542A (ko) 2019-06-10
AU2013282395C1 (en) 2016-03-24
PH12015502408A1 (en) 2018-03-26
PH12014502871A1 (en) 2015-02-23
KR20140004603A (ko) 2014-01-13
HK1209431A1 (en) 2016-04-01
PT2867245T (pt) 2018-11-26
HRP20181897T1 (hr) 2019-01-11
JP2018121645A (ja) 2018-08-09
UA121959C2 (uk) 2020-08-25
MX336715B (es) 2016-01-28
MY180287A (en) 2020-11-27
EP3441398A1 (en) 2019-02-13
EA202090044A1 (ru) 2020-07-31
CL2014003567A1 (es) 2015-04-24
IL287057A (en) 2021-12-01
HUE040769T2 (hu) 2019-03-28
PL2867245T3 (pl) 2019-02-28
SI2867245T1 (sl) 2018-12-31
TW201410868A (zh) 2014-03-16
AU2018200230B2 (en) 2020-01-02
US20140004096A1 (en) 2014-01-02
JP2016119911A (ja) 2016-07-07
TR201815811T4 (tr) 2018-11-21
CA3008945A1 (en) 2014-01-03
AU2016200469A1 (en) 2016-02-18
EA201492177A1 (ru) 2015-06-30
DK2867245T3 (en) 2018-11-26
CN107596357A (zh) 2018-01-19
US20150313972A1 (en) 2015-11-05
PE20150720A1 (es) 2015-05-16
PH12015502408B1 (en) 2020-02-14
BR112014032567B1 (pt) 2022-09-13
EP2867245A4 (en) 2016-03-09
MX366906B (es) 2019-07-30
KR20200143339A (ko) 2020-12-23
US20240401010A1 (en) 2024-12-05
US10344270B2 (en) 2019-07-09
KR20140002451A (ko) 2014-01-08
EA034549B1 (ru) 2020-02-19
SG10201703489VA (en) 2017-05-30
CN104583225A (zh) 2015-04-29
JP2020105209A (ja) 2020-07-09
EP2867245B1 (en) 2018-09-12
TWI587869B (zh) 2017-06-21
AU2013282395A1 (en) 2015-01-29
IL248727A0 (en) 2017-01-31
GT201400303A (es) 2017-08-31
CR20140588A (es) 2015-04-06
HK1209767A1 (en) 2016-04-08
AR091647A1 (es) 2015-02-18
EP2867245A2 (en) 2015-05-06
MY192068A (en) 2022-07-25
NZ703093A (en) 2017-08-25
JP6505629B2 (ja) 2019-04-24
DOP2014000294A (es) 2015-03-15
ZA201803289B (en) 2021-04-28
US20170073652A1 (en) 2017-03-16
US9492511B2 (en) 2016-11-15
WO2014005014A3 (en) 2014-02-27
WO2014005014A2 (en) 2014-01-03

Similar Documents

Publication Publication Date Title
NZ733366A (en) Purification of iduronate-2-sulfatase
MY171146A (en) Compositions of glp-1 peptides and preparation thereof
MX2013013913A (es) Polipeptidos.
PH12014500922A1 (en) Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
MX2013001540A (es) Composiciones que comprende un polipeptido que tiene actividad de incremento celulolititico y un compuesto de quinona, y uso de las mismas.
UA103526C2 (ru) Воспроизведенный сурфактант, который содержит аналоги белков естественных сурфактантов sp-b и sp-c
IN2015KN00262A (cg-RX-API-DMAC7.html)
MX2013001677A (es) Formulaciones estables de linaclotida.
TN2011000370A1 (en) Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
MY165152A (en) Cyclosporine analogue molecules modified at amino acid 1 and 3
UA109949C2 (uk) Композиція і лікарський засіб, які містять ідуронат-2-сульфатазу, і спосіб їх отримання
IN2014DN09922A (cg-RX-API-DMAC7.html)
MX2011012643A (es) 2,4-diaminopiridinas para el tratamiento de enfermedades caracterizadas por la proliferacion celular excesiva o anormal.
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
MX344815B (es) Metodo para purificar el factor estimulante de colonias de granulocitos humano a partir de e. coli recombinante.
ZA201202491B (en) Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same
UA108636C2 (xx) Пептид
IN2012DN01292A (cg-RX-API-DMAC7.html)
MY169650A (en) Crystalline recombinant interferon with altered spatial configuration,three-dimensional structure and uses thereof
IN2014DN09963A (cg-RX-API-DMAC7.html)
WO2012128582A3 (en) A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
NZ601142A (en) Composition for improving brain function and method for improving brain function
WO2010119450A3 (en) An improved process for the preparation of desmopressin or its pharmaceutically acceptable salts
JO2857B1 (en) Vinyl pipers with modified activity of tumor-resistant TNF
TN2011000617A1 (en) 17 - alkyl-17 -oxy-oestratrienes

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2021 BY ANAQUA SERVICES

Effective date: 20200520

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2022 BY ANAQUA SERVICES

Effective date: 20210519

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2023 BY ANAQUA SERVICES

Effective date: 20220523

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2024 BY ANAQUA SERVICES

Effective date: 20230524

ASS Change of ownership

Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP

Effective date: 20231115

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2025 BY ANAQUA SERVICES

Effective date: 20240521

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2026 BY ANAQUA SERVICES

Effective date: 20250520